USANA Health Sciences (USNA) Q3 2024 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2024 earnings summary
19 Jan, 2026Executive summary
Q3 2024 net sales declined 6.2% year-over-year to $200.2 million, with diluted EPS at $0.56, down from $0.59 in Q3 2023, and active customers decreased to 452,000.
Net earnings for Q3 2024 were $10.6 million, down from $11.3 million in Q3 2023, reflecting lower sales and higher operating expenses.
Management cited continued headwinds in key markets, especially China, but highlighted progress on strategic initiatives, product innovation, and global expansion, including India.
The company operates in 25 markets, with about 90% of net sales generated outside the US, and maintains a low capital intensity business model with strong cash flow and no debt.
Increased promotional activity is planned for Q4 to support business momentum, with updated fiscal 2024 guidance reflecting these efforts.
Financial highlights
Q3 2024 net sales were $200.2 million, down 6.2% year-over-year; net earnings were $10.6 million, and diluted EPS was $0.56.
Gross margin for Q3 2024 was 80.4%, up from 80.1% in Q3 2023, driven by lower material costs and favorable market mix.
Cash and cash equivalents as of Q3 2024 were $365 million, with no debt.
Free cash flow for the trailing twelve months was $74 million, with a free cash flow margin of 9%.
Operating cash flow for the first nine months of 2024 was $55.2 million, up from $44.6 million in the prior-year period.
Outlook and guidance
Fiscal 2024 net sales guidance is $850 million, with diluted EPS of $2.45 and operating margin of 8.5%.
Fourth quarter guidance includes higher promotional spending, expected to impact margins and EPS.
Management does not expect recent stimulus in China to impact near-term results.
Product pipeline for 2025 is robust, with significant upgrades and new launches planned, especially in the nutritionals category.
Remediation of material weaknesses in IT general controls is ongoing, with completion expected before year-end 2024.
Latest events from USANA Health Sciences
- 2026 outlook targets 4%–8% sales growth, led by retail expansion and strategic investments.USNA
Q4 202518 Feb 2026 - Hiya acquisition and agile innovation drive growth, with China and global markets as key priorities.USNA
Sidoti Small-Cap Virtual Conference3 Feb 2026 - Q2 sales and EPS declined sharply, but strong liquidity supports ongoing strategic initiatives.USNA
Q2 20243 Feb 2026 - Active associate growth and accelerated product innovation drive global expansion and future growth.USNA
Small-Cap Growth Virtual Investor Conference1 Feb 2026 - China drives short-term gains as focus shifts to associates, innovation, and disciplined growth.USNA
Water Tower Research Consumer Products Virtual Investor Conference 20241 Feb 2026 - Omnichannel brands and retail expansion are driving rapid growth and diversification.USNA
28th Annual ICR Conference 202612 Jan 2026 - $205M acquisition of a children's wellness brand accelerates growth and market leadership.USNA
M&A Announcement10 Jan 2026 - Acquisition of Hiya Health accelerates growth in children's supplements and expands market reach.USNA
27th Annual ICR Conference 202510 Jan 2026 - Q1 2025 net sales up 9.5–12% to $249.5M, but net earnings fell 43% to $9.4M.USNA
Q1 202527 Dec 2025